The influence of preanalytical conditions on the DJ-1 concentration in human cerebrospinal fluid

Biomarkers in Medicine

Volumn 8, Issue 3, 2014, Pages 387-394

  Salvesen, Lisette ^a   Tanassi, Julia T ^b   Bech, Sara ^a,c   Pålhagen, Sven ^d   Svenningsson, Per ^d   Heegaard, Niels H H ^b   Winge, Kristian ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

biomarkers; centrifugation; cerebrospinal fluid; DJ 1; hemoglobin; Parkinson's disease; preanalytical factors; protease inhibitors

Indexed keywords

DJ 1 PROTEIN; HEMOGLOBIN; PROTEINASE INHIBITOR; BIOLOGICAL MARKER; ONCOPROTEIN; PARK7 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD CONTAMINATION; CENTRIFUGATION; CONTAMINATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GRAVITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TEMPERATURE SENSITIVITY; CEREBROSPINAL FLUID; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE COUNT; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; BIOLOGICAL MARKERS; CENTRIFUGATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE COUNT; FEMALE; HEMOGLOBINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; ONCOGENE PROTEINS; PARKINSON DISEASE; PROTEASE INHIBITORS;

EID: 84898413886     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.125     Document Type: Article

References (21)

1. Chahine L, Stern MB. Diagnostic markers for Parkinson's disease. Curr. Opin. Neurol. 24, 309-317 (2011).
2. Nagakubo D, Taira T, Kitaura H et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem. Biophys. Res. Commun. 231, 509-513 (1997).
3. Batelli S, Albani D, Rametta R et al. DJ-1 modulates α-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70. PLoS ONE 3(4), e1884 (2008).
4. Bonifati V, Rizzu P, van Baren MJ et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259 (2003).
5. Neumann M, Müller V, Görner K, Kretzschmar HA, Haass C, Kahle PJ. Pathological properties of the Parkinson's disease associated protein DJ-1 in α-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease. Acta Neuropathol. 107, 489-496 (2004).
6. Trojanovski JQ, Revesz T. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol. Appl. Neurobiol. 33(6), 615-620 (2007).
7. Hong Z, Shi M, Chung KA et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133, 713-726 (2010).
8. Shi M, Bradner J, Hancock AM et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 69, 570-580 (2011).
9. Salvesen L, Bech S, Lokkegaard A et al. The DJ-1 concentration in cerebrospinal fluid does not differentiate among parkinsonian syndromes. Parkinsonism Relat. Disord. 18(7), 899-901 (2012).
10. Waragai M, Wei J, Fujita M et al. Increased level of DJ-1 in the cerebrospinal fluid of sporadic Parkinson's disease. Biochem. Biophys. Res. Commun. 345, 967-972 (2006).
11. Shi M, Zabetian CP, Hancock AM et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson disease. Neurosci. Lett. 480(1), 78-82 (2010).
12. del Campo M, Mollenhauer B, Bertolotto A et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomarkers Med. 6(4), 419-430 (2012).
13. Emre M, Aarsland D, Brown R et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov. Disord. 22(12), 1689-1707 (2007).
14. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann. Neurol. 32(Suppl.), 125-127 (1992).
15. Pålhagen S, Qi H, Martensson B, Walinder J, Granerus AK, Svenningsson P. Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. J. Neurol. 257, 524-532 (2010).
16. Maita C, Tsuji S, Yabe I et al. Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci. Lett. 431, 86-89 (2008).
17. Hirotani M, Maita C, Niino M et al. Correlation between DJ-1 levels in the cerebrospinal fluid and the progression of disabilities in multiple sclerosis patients. Mult. Scler. 14, 1056-1060 (2008).
18. Berven FS, Kroksveen AC, Berle M et al. Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. Proteomics Clin. Appl. 1, 699-711 (2007).
19. You J-S, Gelfanova V, Knierman MD, Witzmann FA, Wang M, Hale JE. The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics 5, 290-296 (2005).
20. Schuchard MD, Mehigh RJ Cockrill SL et al. Artifactual isoform profile modification following treatment of human plasma or serum with protease inhibitor, monitored by 2-dimensional electrophoresis and mass spectrometry. Biotechniques 39, 239-247 (2005).
21. Simonsen AH, Bahl J, Danborg PB et al. Pre-analytical factors influencing the stability of cerebrospinal fluid proteins. J. Neurosci. Methods 215(2), 234-240 (2013).